An Australian translational Study to evaluate the prognostic role of inflammatory markers in patients with metastatic ColorEctal caNcer Treated with bevacizumab (Avastin™) [ASCENT]
© Clarke et al; licensee BioMed Central Ltd. 2013
Received: 15 August 2012
Accepted: 8 March 2013
Published: 15 March 2013
Open Peer Review reports
Pre-publication versions of this article and author comments to reviewers are available by contacting email@example.com.
|15 Aug 2012||Submitted||Original manuscript|
|Resubmission - Version 2|
|Submitted||Manuscript version 2|
|2 Nov 2012||Reviewed||Reviewer Report - Stephen Falk|
|13 Nov 2012||Reviewed||Reviewer Report - Paul Ross|
|13 Nov 2012||Reviewed||Reviewer Report - raffaele palmirotta|
|16 Dec 2012||Author responded||Author comments - Cassandra Cordwell|
|Resubmission - Version 3|
|16 Dec 2012||Submitted||Manuscript version 3|
|8 Mar 2013||Editorially accepted|
|15 Mar 2013||Article published||10.1186/1471-2407-13-120|
How does Open Peer Review work?
Open peer review is a system where authors know who the reviewers are, and the reviewers know who the authors are. If the manuscript is accepted, the named reviewer reports are published alongside the article. Pre-publication versions of the article and author comments to reviewers are available by contacting firstname.lastname@example.org. All previous versions of the manuscript and all author responses to the reviewers are also available.
You can find further information about the peer review system here.